KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Current Assets (2019 - 2025)

Historic Current Assets for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $1.8 billion.

  • Royalty Pharma's Current Assets rose 308.45% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year increase of 308.45%. This contributed to the annual value of $1.8 billion for FY2024, which is 4143.38% up from last year.
  • Latest data reveals that Royalty Pharma reported Current Assets of $1.8 billion as of Q3 2025, which was up 308.45% from $1.5 billion recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Current Assets registered a high of $3.5 billion during Q2 2022, and its lowest value of $1.3 billion during Q4 2023.
  • Over the past 5 years, Royalty Pharma's median Current Assets value was $2.4 billion (recorded in 2021), while the average stood at $2.3 billion.
  • In the last 5 years, Royalty Pharma's Current Assets plummeted by 5012.76% in 2023 and then skyrocketed by 4143.38% in 2024.
  • Royalty Pharma's Current Assets (Quarter) stood at $2.9 billion in 2021, then decreased by 11.23% to $2.6 billion in 2022, then tumbled by 50.13% to $1.3 billion in 2023, then skyrocketed by 41.43% to $1.8 billion in 2024, then rose by 2.63% to $1.8 billion in 2025.
  • Its last three reported values are $1.8 billion in Q3 2025, $1.5 billion for Q2 2025, and $1.8 billion during Q1 2025.